Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.45 |
| ▸ | TERF2 | Q15554 | 5/20 | 0.39 |
| ▸ | CTSC | P53634 | 4/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26679247 | 1.00 | ESR1 (0.51) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL22429493 | 1.00 | ESR1 (0.51) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL22429540 | 0.90 | CACNA1C (0.50) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL26678817 | 0.90 | CACNA1C (0.50) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL26678826 | 0.90 | CACNA1C (0.50) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL22429572 | 0.89 | CACNA1C (0.49) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL26679019 | 0.89 | CACNA1C (0.49) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL22429138 | 0.89 | CACNA1C (0.49) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL22429896 | 0.89 | CACNA1C (0.49) | ESR1PTGS1PDE4ACACNA1CABCC2 | |
| SCHEMBL22429544 | 0.88 | ESR1 (0.52) | ESR1PTGS1PDE4ACACNA1CABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3430013-B1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD (IN) | 2023-11-15 | — | — | EP | disclosed |
| EP-3430013-B1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD (IN) | 2023-11-15 | — | — | EP | disclosed |
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | ORCHID PHARMA LTD. (IN) | 2021-11-23 | — | — | US | disclosed |
| US-20200291029-A1 | CARBAPENEM COMPOUNDS | MERCK SHARP & DOHME CORP. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | SLC11A2, GSK3B, GSK3A | ESR1 1298/4885PTGS1 2147/4885PDE4A 1205/4885 |
| US-20200291029-A1 | CARBAPENEM COMPOUNDS | GSK3B, GSK3A, GNE | ESR1 2445/4885PTGS1 1600/4885PDE4A 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.